Starling Oncology, Inc.
STLN- Exchange
- Nasdaq
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 119 institutions reported holding it in 13F filings for Q2 2026, worth $217.6M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Starling Oncology, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 39 | 1 | 40 | +2 |
| Shares | 23.4M | 240.7K | 23.5M | +403.7K (+1.7%) |
| Value | $108.4M | $1.11M | $38.7M | −$68.6M (−63.9%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Starling Oncology, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Prosight Management, LP | 275,561 | $454.7K | 0.25% |
| Jefferies Financial Group Inc. | 192,452 | $317.5K | 0.01% |
| Josh Arnold Investment Consultant, LLC | 104,400 | $172.0K | 0.25% |
| Two Sigma Investments, LP | 50,492 | $83.3K | 0.00% |
| Alpine Global Management, LLC | 46,326 | $76.0K | 0.03% |
| CI Private Wealth, LLC | 12,500 | $21.0K | 0.00% |
| Federated Hermes, Inc. | 6,697 | $11.1K | 0.00% |
| Nisa Investment Advisors, LLC | 13 | $0 | 0.00% |
Sold out (6)
Institutions that held Starling Oncology, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Velan Capital Investment Management LP | 548,841 | $2.54M |
| Zebra Capital Management LLC | 27,484 | $127.0K |
| First Republic Investment Management, Inc. | 18,300 | $85.0K |
| Voya Investment Management LLC | 13,781 | $63.8K |
| Susquehanna International Group, LLP | 10,525 | $49.0K |
| Wells Fargo & Company | 568 | $3.00K |
Not filed for Q4 2022 yet (1)
Institutions that held Starling Oncology, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Parian Global Management LP | 240,724 | $1.11M |